Armata Pharmaceuticals, Inc.

ARMPSEC EDGAR

Biological Products, (No Diagnostic Substances)(WA)CIK: 921114

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	—	—	—	—	—
Operating Expenses	$45.4M	$42.5M	$28.3M	$22.4M	$19.8M
Operating Income (Loss)	-$40.9M	-$36.9M	-$23.8M	-$21.6M	-$19.8M
Interest Expense	—	—	$64.0K	$628.0K	$931.0K
Other Nonoperating Income (Expense)	-$28.2M	$29.0K	$667.0K	-$594.0K	$273.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$69.0M	-$36.9K	-$23.2M	-$22.2M	—
Income Tax Expense (Benefit)	—	—	—	—	—
Net Income (Loss) Attributable to Parent	-$69.0M	-$36.9M	-$23.2M	-$22.2M	-$19.5M
Earnings Per Share, Basic	-$1.91	-$1.08	-$0.96	-$1.35	-$2.49
Earnings Per Share, Diluted	-$1.91	-$1.08	-$0.96	-$1.35	-$2.55

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$98.4M	$95.8M	$69.8M	$39.5M	$25.5M
Assets, Current	$19.2M	$27.0M	$15.0M	$10.8M	$6.7M
Cash and Cash Equivalents, at Carrying Value	$13.5M	$14.9M	$10.3M	$9.6M	$6.0M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	—	—
Liabilities	$130.4M	$59.8M	$44.4M	$20.7M	$10.9M
Liabilities, Current	$16.5M	$24.9M	$4.8M	$6.7M	$4.9M
Accounts Payable, Current	$1.6M	$1.7M	$1.1M	$956.0K

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$47.4M	-$32.5M	-$23.6M	-$18.3M	-$15.6M
Net Cash Provided by (Used in) Investing Activities	-$8.1M	-$2.2M	-$1.3M	-$824.0K	$2.9M
Net Cash Provided by (Used in) Financing Activities	$54.0M	$44.0M	$25.5M	$23.2M	$9.0M
Payments to Acquire Property, Plant, and Equipment	$8.1M	$2.2M	$1.3M	$824.0K	$224.0K
Payments of Dividends	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)